Answers are grounded in this paper and cite their sources.
Background This pooled data analysis aimed to clarify the effectiveness of micronized purified flavonoid fraction (MPFF) in improving quality-of-life (QoL) across the spectrum of chronic venous disease (CVD) in routine clinical practice. Methods Observational studies conducted in Russian populations assessing the effectiveness of MPFF-based therapy as part of the Russian Vein Act Prolonged program were identified. Primary endpoint was change in QoL over time (CIVIQ-14). Secondary endpoints included change in severity of self-assessed symptoms on a visual analog scale (VAS) and change in the proportion of patients with venous reflux. The systematic review protocol for this study was not prospectively registered. Results Five observational studies involving 4091 participants in CEAP classes C1−C4 and C6 were included. MPFF-based conservative therapy was associated with a statistically significant improvement in CIVIQ-14 global index score at the end of the observational period compared with baseline (SMD [95% CI] 1.29 [1.04, 1.55], p < 0.0001). Improvements were also observed in each CIVIQ-14 dimension: pain (1.50 [1.19, 1.82]; p < 0.0001), physical (0.90 [0.59, 1.20]; p < 0.0001), and psychological (1.03 [0.83, 1.23]; p < 0.0001). Analysis of VAS-assessed symptom severity indicated MPFF-based therapy was associated with statistically significant improvements in leg pain ( p < 0.0001), leg itching ( p < 0.0009), and leg heaviness, leg swelling, and night cramps (all p < 0.0001) compared with baseline. MPFF-based therapy was associated with a statistically significant reduction in the odds ratio of reflux in patients with CEAP classes C2–C4 and C6 (OR 0.1; 95% CI 0.0, 0.5; p < 0.01). High heterogeneity of the results was observed for all parameters studied. Conclusions This pooled data analysis indicated that MPFF-based therapy was associated with improvements in overall QoL score as well as the pain, physical and psychosocial dimensions. MPFF treatment was also associated with improvements in leg symptoms and reduced the proportion of patients suffering from venous reflux across the range of CEAP classes.
No takes yet. Share an insight, caveat, or question.
Bogachev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: